Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Healthcare Life Sciences Launches Xuri™ Technology Family

Published: Wednesday, November 13, 2013
Last Updated: Wednesday, November 13, 2013
Bookmark and Share
First product introduced - Xuri Cell Expansion System W25 for the clinical manufacture of cellular immunotherapies.

GE Healthcare Life Sciences has launched Xuri™, a new technology family designed specifically to support and advance the field of cell therapy.

The new technology family, in which the first product is the Xuri Cell Expansion System W25 for the manufacture of cellular immunotherapies in a clinical setting, will combine GE Healthcare’s capabilities in cellular science with the company’s expertise in the development of advanced tools for the manufacture of biopharmaceuticals.

Cell therapy and regenerative medicine, the use of cells to replace damaged tissue or to treat disease, shows great promise for treating many life-threatening and life-limiting illnesses such as cancer, heart disease, Parkinson’s and age-related macular degeneration.

The widespread adoption of these therapies will require the development of robust, scalable manufacturing tools and workflows to generate sufficient, high quality cells for infusion into patients.

With an estimated 2,500 on-going cell therapy and regenerative medicine clinical trials worldwide, many research groups are now looking at how to move from small-scale expansion of cells to a cost-effective, industrialized process.

GE Healthcare’s new Xuri Cell Expansion System W25 is a functionally closed, automated system, specifically designed to be suitable for the requirements of scaling-out cell therapies in a clinical setting.

The system is equipped with dedicated software applications to make it suitable for a regulated manufacturing environment and has been validated for T-cell growth.

The Xuri W25 builds on the GE Healthcare’s WAVE Bioreactor™ technology which is widely used in the development and manufacture of biopharmaceuticals globally.

Eric Roman, General Manager of Research & Applied Markets, GE Healthcare Life Sciences, commented, “Through our scale and innovation, we are committed to addressing the significant challenges that remain in moving from highly promising experimental cell therapies to widely available and affordable treatments. We have an extensive research program, working with leaders in the field such as the Karolinska University Hospital, to develop tailored technologies and workflows. The focus of our Xuri technology family is to enable the safe, reliable and efficient progress of cell therapies from clinical development to commercialization.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare Life Sciences Completes Acquisition of Xcellerex, Inc.
Acquisition expands GE Healthcare’s offering of technologies and services for the manufacture of recombinant proteins, antibodies and vaccines.
Tuesday, May 15, 2012
Scientific News
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
Intestinal Worms Boost Immune System In A Surprising Way
EPFL researchers find that intestinal worm infections cause lymph nodes to produce more immune cells as well as grow in size.
Breast Milk Hormones Impact Bacteria In Infants’ Guts
Intestinal microbiome of children born to obese mothers significantly different from those born to mothers of healthy weight, CU Anschutz researchers find.
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Gut Microbiomes Of Infants Have An Impact On Autoimmunity
Exposure to pathogens early in life is beneficial to the education and development of the human immune system.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!